BACKGROUND AND AIMS: This study evaluated the responses to soluble epoxide hydrolase (s-EH) inhibition, an essential enzyme in the metabolism of arachidonic acid, on food intake, body weight and metabolic parameters in mice fed a high fat-high fructose diet (HFD) for 10 weeks. METHODS AND RESULTS: After 5 weeks of HFD, mice were divided into two groups: 1) s-EH inhibitor (AR9281, 200mg/kg/day by gavage twice daily), and 2) vehicle (0.3ml per gavage). Food intake, body weight, oxygen consumption (VO(2)), carbon dioxide production (VCO(2)), respiratory quotient (RQ), and motor activity were measured weekly for more 5 weeks. HFD increased body weight (37±1 vs. 26±1g), and plasma of glucose (316±8 vs. 188±27mg/dl), insulin (62.1±8.1 vs. 15.5±5.0μU/ml), and leptin levels (39.4±3.6 vs. 7.5±0.1ng/ml) while reducing VO(2), VCO(2) and motor activity. s-EH inhibition for 5 weeks decreased caloric intake by ~32% and increased VO(2) by ~17% (42.8±1.4 vs. 50.2±1.5ml/kg/min) leading to significant weight loss. Inhibition of s-EHi also caused significant reductions in plasma leptin levels and visceral fat content. Uncoupling protein 1 (UCP1) content in brown adipose tissue was also elevated by ~50% during s-EH inhibition compared to vehicle treatment. CONCLUSION: These results suggest that s-EH inhibition with AR9281 promotes weight loss by reducing appetite and increasing metabolic rate, and that increased UCP1 content may contribute to the increase in energy expenditure.
BACKGROUND AND AIMS: This study evaluated the responses to soluble epoxide hydrolase (s-EH) inhibition, an essential enzyme in the metabolism of arachidonic acid, on food intake, body weight and metabolic parameters in mice fed a high fat-high fructose diet (HFD) for 10 weeks. METHODS AND RESULTS: After 5 weeks of HFD, mice were divided into two groups: 1) s-EH inhibitor (AR9281, 200mg/kg/day by gavage twice daily), and 2) vehicle (0.3ml per gavage). Food intake, body weight, oxygen consumption (VO(2)), carbon dioxide production (VCO(2)), respiratory quotient (RQ), and motor activity were measured weekly for more 5 weeks. HFD increased body weight (37±1 vs. 26±1g), and plasma of glucose (316±8 vs. 188±27mg/dl), insulin (62.1±8.1 vs. 15.5±5.0μU/ml), and leptin levels (39.4±3.6 vs. 7.5±0.1ng/ml) while reducing VO(2), VCO(2) and motor activity. s-EH inhibition for 5 weeks decreased caloric intake by ~32% and increased VO(2) by ~17% (42.8±1.4 vs. 50.2±1.5ml/kg/min) leading to significant weight loss. Inhibition of s-EHi also caused significant reductions in plasma leptin levels and visceral fat content. Uncoupling protein 1 (UCP1) content in brown adipose tissue was also elevated by ~50% during s-EH inhibition compared to vehicle treatment. CONCLUSION: These results suggest that s-EH inhibition with AR9281 promotes weight loss by reducing appetite and increasing metabolic rate, and that increased UCP1 content may contribute to the increase in energy expenditure.
Authors: John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock Journal: Hypertension Date: 2005-09-12 Impact factor: 10.190
Authors: Jeffrey J Olearczyk; Jeffrey E Quigley; Bradford C Mitchell; Tatsuo Yamamoto; In-Hae Kim; John W Newman; Ayala Luria; Bruce D Hammock; John D Imig Journal: Clin Sci (Lond) Date: 2009-01 Impact factor: 6.124
Authors: Hui Huang; Christophe Morisseau; JingFeng Wang; Tianxin Yang; John R Falck; Bruce D Hammock; Mong-Heng Wang Journal: Am J Physiol Renal Physiol Date: 2007-04-18
Authors: Xizhen Xu; Chun Xia Zhao; Luyun Wang; Ling Tu; Xiaosai Fang; Changlong Zheng; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang Journal: Diabetes Date: 2010-01-12 Impact factor: 9.461
Authors: James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song Journal: Adv Pharmacol Date: 2013
Authors: Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan Journal: Prog Neurobiol Date: 2018-11-14 Impact factor: 11.685
Authors: Jussara M do Carmo; Alexandre A da Silva; John Nathan Freeman; Zhen Wang; Sydney P Moak; Michael W Hankins; Heather A Drummond; John E Hall Journal: Hypertension Date: 2018-04-23 Impact factor: 10.190
Authors: Suman Kundu; Talat Roome; Ashish Bhattacharjee; Kevin A Carnevale; Valentin P Yakubenko; Renliang Zhang; Sung Hee Hwang; Bruce D Hammock; Martha K Cathcart Journal: J Lipid Res Date: 2012-11-15 Impact factor: 5.922
Authors: Houli Jiang; Fiona E Harrison; Kavita Jain; Samantha Benjamin; James M May; Joan P Graves; Darryl C Zeldin; John R Falck; Bruce D Hammock; John C McGiff Journal: Adv Biosci Biotechnol Date: 2012-06-01